Clinical Trials · NCT03086330
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 302
- Start date
- Mar 2017
- Locations
- 72 sites, 7 countries
- Primary endpoint
- Change in HbA1c